156 related articles for article (PubMed ID: 15731738)
1. Therapeutic drug monitoring of antiretroviral agents scenario.
Moltó J; Clotet B
J HIV Ther; 2004 Nov; 9(4):75-8. PubMed ID: 15731738
[TBL] [Abstract][Full Text] [Related]
2. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
Justesen US
Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefit of interventions driven by therapeutic drug monitoring.
Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of antiretroviral agents.
Bean P; Patnaik M; Graziano FM; Aziz DC
Am Clin Lab; 2000 May; 19(4):20-2. PubMed ID: 10947316
[TBL] [Abstract][Full Text] [Related]
5. [The value of plasma antiretroviral drug monitoring in the management of HIV infected patients].
Tréluyer JM
Ann Med Interne (Paris); 2000 Jun; 151(4):291-6. PubMed ID: 10922957
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.
Justesen US
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):20-31. PubMed ID: 16433887
[TBL] [Abstract][Full Text] [Related]
7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
8. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
Gupta SB; Pujari SN; Joshi SR; Patel AK;
J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
[TBL] [Abstract][Full Text] [Related]
9. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection.
Pretorius E; Klinker H; Rosenkranz B
Ther Drug Monit; 2011 Jun; 33(3):265-74. PubMed ID: 21566505
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
[TBL] [Abstract][Full Text] [Related]
11. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
[TBL] [Abstract][Full Text] [Related]
13. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.
Boffito M; Acosta E; Burger D; Fletcher CV; Flexner C; Garaffo R; Gatti G; Kurowski M; Perno CF; Peytavin G; Regazzi M; Back D
Antivir Ther; 2005; 10(3):375-92. PubMed ID: 15918329
[TBL] [Abstract][Full Text] [Related]
14. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring.
Flexner CW
Top HIV Med; 2003; 11(2):40-4. PubMed ID: 12717040
[TBL] [Abstract][Full Text] [Related]
15. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
16. The use of therapeutic drug monitoring in the management of protease inhibitor-related toxicity.
Forsyth SF; French PD; Macfarlane E; Gibbons SE; Miller RF
Int J STD AIDS; 2005 Feb; 16(2):139-41. PubMed ID: 15807942
[TBL] [Abstract][Full Text] [Related]
17. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring in highly active antiretroviral therapy.
Liu X; Ma Q; Zhang F
Expert Opin Drug Saf; 2010 Sep; 9(5):743-58. PubMed ID: 20350281
[TBL] [Abstract][Full Text] [Related]
19. Predictors of short-term success of antiretroviral therapy in HIV infection.
Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
[TBL] [Abstract][Full Text] [Related]
20. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults.
van der Leur MR; Burger DM; la Porte CJ; Koopmans PP
Ther Drug Monit; 2006 Oct; 28(5):650-3. PubMed ID: 17038880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
